Payment overview · 2025
General Payments
$416.72
21 reported records · 10 companies
Healthcare provider profile · identity verified
Paul S Holley, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · BEMUS POINT, NY · NPI 1225015696
Verified facts
What the public records show
CMS Open Payments records show Paul S Holley, M.D. received $416.72 in general payments during 2025 across 21 reported records.
Novo Nordisk Inc accounted for 37.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $156.76 | 37.6% | 8 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $66.32 | 15.9% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $40.24 | 9.7% | 2 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $36.17 | 8.7% | 2 | 2025 |
| ALK-Abello, Inc | Unresolved — no canonical attribution shown | $26.33 | 6.3% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $20.82 | 5.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $19.52 | 4.7% | 1 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $17.34 | 4.2% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $17.14 | 4.1% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $16.08 | 3.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $416.72 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $45.32 | 2 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $36.17 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $33.17 | 2 | 2025 |
Source payment records
|
|||||
| Grastek Normalized: grastek |
Drug | ALK-Abello, Inc | $26.33 | 1 | 2025 |
Source payment records
|
|||||
| Odactra Normalized: odactra |
Drug | ALK-Abello, Inc | $26.33 | 1 | 2025 |
Source payment records
|
|||||
| Ragwitek Normalized: ragwitek |
Drug | ALK-Abello, Inc | $26.33 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $22.63 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $21.00 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $20.82 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $20.35 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $19.52 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $19.46 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $17.61 | 1 | 2025 |
Source payment records
|
|||||
| Jornay PM Normalized: jornay pm |
Drug | Collegium Pharmaceutical, Inc. | $17.34 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $17.14 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $17.14 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $16.08 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $16.08 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $13.80 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 67 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 56 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 44 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
60 | 18 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
67 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
56 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 449 | 122 |
| Lisinopril | Lisinopril | 422 | 125 |
| Amlodipine Besylate | Amlodipine Besylate | 307 | 86 |
| Atorvastatin Calcium | Atorvastatin Calcium | 286 | 84 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 238 | 39 |
| Prednisone | Prednisone | 227 | 105 |
| Famotidine | Famotidine | 218 | 55 |
| Metoprolol Succinate | Metoprolol Succinate | 214 | 65 |
| Hydrochlorothiazide | Hydrochlorothiazide | 193 | 56 |
| Omeprazole | Omeprazole | 154 | 52 |
| Metoprolol Tartrate | Metoprolol Tartrate | 138 | 35 |
| Tramadol Hcl | Tramadol Hcl | 131 | 32 |
| Meloxicam | Meloxicam | 130 | 27 |
| Eliquis | Apixaban | 127 | 27 |
| Metformin Hcl | Metformin Hcl | 126 | 41 |
| Gabapentin | Gabapentin | 121 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 118 | 32 |
| Furosemide | Furosemide | 115 | 35 |
| Pantoprazole Sodium | Pantoprazole Sodium | 112 | 30 |
| Zolpidem Tartrate | Zolpidem Tartrate | 109 | 16 |
| Alprazolam | Alprazolam | 101 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 100 | 24 |
| Fenofibrate | Fenofibrate | 100 | 32 |
| Montelukast Sodium | Montelukast Sodium | 100 | 21 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 100 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 89 | 31 |
| Citalopram Hbr | Citalopram Hydrobromide | 82 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 82 | 29 |
| Losartan Potassium | Losartan Potassium | 82 | 26 |
| Alendronate Sodium | Alendronate Sodium | 81 | 14 |
| Potassium Chloride | Potassium Chloride | 78 | 21 |
| Simvastatin | Simvastatin | 78 | 23 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 76 | 22 |
| Allopurinol | Allopurinol | 70 | 18 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 68 | 15 |
| Atenolol | Atenolol | 67 | 20 |
| Glipizide Er | Glipizide | 67 | 20 |
| Jardiance | Empagliflozin | 67 | 21 |
| Valsartan | Valsartan | 64 | 17 |
| Tamsulosin Hcl | Tamsulosin Hcl | 62 | 18 |
| Synthroid | Levothyroxine Sodium | 60 | 18 |
| Doxycycline Hyclate | Doxycycline Hyclate | 57 | 49 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 57 | suppressed |
| Rybelsus | Semaglutide | 56 | 12 |
| Sertraline Hcl | Sertraline Hcl | 54 | 22 |
| Fenofibrate | Fenofibrate Nanocrystallized | 53 | suppressed |
| Fluconazole | Fluconazole | 52 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 52 | suppressed |
| Xarelto | Rivaroxaban | 52 | 11 |
| Donepezil Hcl | Donepezil Hcl | 50 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 49 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 49 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 47 | 40 |
| Ezetimibe | Ezetimibe | 44 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 44 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 43 | suppressed |
| Celecoxib | Celecoxib | 40 | 14 |
| Mounjaro | Tirzepatide | 40 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 39 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 38 | 29 |
| Clindamycin Hcl | Clindamycin Hcl | 38 | 28 |
| Ibuprofen | Ibuprofen | 38 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 38 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 38 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 36 | 11 |
| Ondansetron Odt | Ondansetron | 36 | suppressed |
| Pregabalin | Pregabalin | 36 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 36 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 35 | suppressed |
| Spironolactone | Spironolactone | 35 | 12 |
| Januvia | Sitagliptin Phosphate | 34 | suppressed |
| Nystatin | Nystatin | 33 | 15 |
| Warfarin Sodium | Warfarin Sodium | 33 | 11 |
| Azithromycin | Azithromycin | 32 | 25 |
| Irbesartan | Irbesartan | 31 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 31 | 12 |
| Carvedilol | Carvedilol | 30 | suppressed |
| Mirtazapine | Mirtazapine | 30 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 29 | 13 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 28 | suppressed |
| Bupropion Xl | Bupropion Hcl | 27 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 27 | suppressed |
| Baclofen | Baclofen | 26 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 26 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 26 | suppressed |
| Carbamazepine | Carbamazepine | 25 | suppressed |
| Bumetanide | Bumetanide | 24 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 24 | 17 |
| Valacyclovir | Valacyclovir Hcl | 24 | 11 |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 23 | suppressed |
| Hydrocortisone | Hydrocortisone | 23 | suppressed |
| Cephalexin | Cephalexin | 22 | 17 |
| Ozempic | Semaglutide | 22 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 22 | suppressed |
| Amoxicillin | Amoxicillin | 21 | 13 |
| Bupropion Hcl Sr | Bupropion Hcl | 21 | suppressed |
| Entresto | Sacubitril/Valsartan | 21 | suppressed |
| Lovastatin | Lovastatin | 21 | suppressed |
| Naproxen | Naproxen | 21 | suppressed |
| Estradiol | Estradiol | 19 | suppressed |
| Invokana | Canagliflozin | 19 | suppressed |
| Sucralfate | Sucralfate | 19 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Lorazepam | Lorazepam | 18 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 18 | suppressed |
| Diazepam | Diazepam | 17 | suppressed |
| Glimepiride | Glimepiride | 17 | suppressed |
| Nabumetone | Nabumetone | 17 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | suppressed |
| Cefdinir | Cefdinir | 16 | 13 |
| Droplet Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Cimetidine | Cimetidine | 15 | suppressed |
| Clonazepam | Clonazepam | 15 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 15 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Torsemide | Torsemide | 15 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Folic Acid | Folic Acid | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Pioglitazone-Metformin | Pioglitazone Hcl/Metformin Hcl | 13 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Qvar Redihaler | Beclomethasone Dipropionate | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $416.72 · 21 records | Novo Nordisk Inc | AIRSUPRA, FARXIGA, Fluad, Flucelvax, Grastek, JARDIANCE, Jornay PM, MOUNJARO, NUZYRA, Odactra, Ozempic, QULIPTA, Ragwitek, Rybelsus, TRELEGY ELLIPTA, UBRELVY, WATCHMAN FLX, Wegovy, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error